Dexrazoxane HCl | CAS#149003-01-0 | cytoprotective agent

Dexrazoxane HCl
featured

WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 562884

CAS#: 149003-01-0 (HCl)

Description: Dexrazoxane is a cardioprotectant. As a derivative of EDTA, dexrazoxane chelates iron and thus reduces the number of metal ions complexed with anthracycline and, consequently, decrease the formation of superoxide radicals. The exact chelation mechanism is unknown, but it has been postulated that dexrazoxane can be converted into ring-opened form intracellularly and interfere with iron-mediated free radical generation that is in part thought to be responsible for anthryacycline induced cardiomyopathy. It was speculated that dexrazoxane could be used for further investigation to synthesize new antimalarial drugs.

Chemical Structure

Dexrazoxane HCl

CAS# 149003-01-0 (HCl)

Instruction

Theoretical Analysis

MedKoo Cat#: 562884
Name: Dexrazoxane HCl
CAS#: 149003-01-0 (HCl)
Chemical Formula: C11H17ClN4O4
Exact Mass: 304.09
Molecular Weight: 304.730
Elemental Analysis: C, 43.36; H, 5.62; Cl, 11.63; N, 18.39; O, 21.00

Price and Availability

Size	Price	Availability
50mg	USD 450	2 Weeks
100mg	USD 750	2 Weeks
200mg	USD 1350	2 Weeks
500mg	USD 2450	2 Weeks
Bulk inquiry Welcome, Customer: Please do not inquire quote if your intended use is for a patient since our products are for research use and for chemical synthesis use, not for human use . For in-stock products, we listed price in the web page. You may inquire prices for which sizes were not listed. If no price is listed, this means the product is not in stock at the moment, which may be available via custom synthesis. For cost-effective reason, minimum order of 1g is requested (typically very expensive). The lead time is usually 2-4 months. Quote of less than 1g will not be provided. MedKoo may not offer quote for below reasons: (1) current available synthetic method appears to be extremely expensive which is obviously not affordable to most customers; (2) Key raw material to make the product is temporally not available; (3) DEA controlled substances; (4) the product is under patent protection in customer’s country.

Related CAS #: 24584-09-6 (free base) 1263283-43-7 (HCl) 149003-01-0 (HCl)

Synonym: Dexrazoxane HCl; Cardioxan; Cardioxane; Dexrazoxane hydrochloride; ICRF 187 hydrochloride; ICRF-187; ICRF187; Savene; Totect; Zinecard;

IUPAC/Chemical Name: 4-[(2S)-2-(3,5-Dioxopiperazin-1-yl)propyl]piperazine-2,6-dione hydrochloride

InChi Key: BIFMNMPSIYHKDN-FJXQXJEOSA-N

InChi Code: InChI=1S/C11H16N4O4.ClH/c1-7(15-5-10(18)13-11(19)6-15)2-14-3-8(16)12-9(17)4-14;/h7H,2-6H2,1H3,(H,12,16,17)(H,13,18,19);1H/t7-;/m0./s1

SMILES Code: O=C(CN(C[C@@H](N1CC(NC(C1)=O)=O)C)C2)NC2=O.[H]Cl

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Instruction:

View handling instruction

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 304.73 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

Mass

Concentration

Volume

M. Wt* g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

Volume (to add to vial)

Mass (in vial)

Desired Reconstitution Concentration

Dilution Calculator

Calculate the dilution required to prepare a stock solution.

Concentration 1

Volume 1

Concentration 2

Volume 2

1: Henriksen PA. Anthracycline cardiotoxicity: an update on mechanisms, monitoring and prevention. Heart. 2018 Jun;104(12):971-977. doi: 10.1136/heartjnl-2017-312103. Epub 2017 Dec 7. Review. PubMed PMID: 29217634.

2: Payne DL, Nohria A. Prevention of Chemotherapy Induced Cardiomyopathy. Curr Heart Fail Rep. 2017 Oct;14(5):398-403. doi: 10.1007/s11897-017-0353-9. Review. PubMed PMID: 28779279.

3: Bansal N, Amdani S, Lipshultz ER, Lipshultz SE. Chemotherapy-induced cardiotoxicity in children. Expert Opin Drug Metab Toxicol. 2017 Aug;13(8):817-832. doi: 10.1080/17425255.2017.1351547. Epub 2017 Jul 13. Review. PubMed PMID: 28679288.

4: Abushouk AI, Ismail A, Salem AMA, Afifi AM, Abdel-Daim MM. Cardioprotective mechanisms of phytochemicals against doxorubicin-induced cardiotoxicity. Biomed Pharmacother. 2017 Jun;90:935-946. doi: 10.1016/j.biopha.2017.04.033. Epub 2017 Apr 26. Review. PubMed PMID: 28460429.

5: McGowan JV, Chung R, Maulik A, Piotrowska I, Walker JM, Yellon DM. Anthracycline Chemotherapy and Cardiotoxicity. Cardiovasc Drugs Ther. 2017 Feb;31(1):63-75. doi: 10.1007/s10557-016-6711-0. Review. PubMed PMID: 28185035; PubMed Central PMCID: PMC5346598.

6: Henninger C, Fritz G. Statins in anthracycline-induced cardiotoxicity: Rac and Rho, and the heartbreakers. Cell Death Dis. 2017 Jan 19;8(1):e2564. doi: 10.1038/cddis.2016.418. Review. PubMed PMID: 28102848; PubMed Central PMCID: PMC5386353.

7: Fojtu M, Gumulec J, Stracina T, Raudenska M, Skotakova A, Vaculovicova M, Adam V, Babula P, Novakova M, Masarik M. Reduction of Doxorubicin-Induced Cardiotoxicity Using Nanocarriers: A Review. Curr Drug Metab. 2017;18(3):237-263. doi: 10.2174/1389200218666170105165444. Review. PubMed PMID: 28059036.

8: Chen JJ, Wu PT, Middlekauff HR, Nguyen KL. Aerobic exercise in anthracycline-induced cardiotoxicity: a systematic review of current evidence and future directions. Am J Physiol Heart Circ Physiol. 2017 Feb 1;312(2):H213-H222. doi: 10.1152/ajpheart.00646.2016. Epub 2016 Dec 6. Review. PubMed PMID: 27923793.

9: Kuriakose RK, Kukreja RC, Xi L. Potential Therapeutic Strategies for Hypertension-Exacerbated Cardiotoxicity of Anticancer Drugs. Oxid Med Cell Longev. 2016;2016:8139861. Epub 2016 Oct 17. Review. PubMed PMID: 27829985; PubMed Central PMCID: PMC5086499.

10: Rygiel K. Benefits of antihypertensive medications for anthracycline- and trastuzumab-induced cardiotoxicity in patients with breast cancer: Insights from recent clinical trials. Indian J Pharmacol. 2016 Sep-Oct;48(5):490-497. Review. PubMed PMID: 27721532; PubMed Central PMCID: PMC5051240.

11: Hutchins KK, Siddeek H, Franco VI, Lipshultz SE. Prevention of cardiotoxicity among survivors of childhood cancer. Br J Clin Pharmacol. 2017 Mar;83(3):455-465. doi: 10.1111/bcp.13120. Epub 2016 Oct 12. Review. PubMed PMID: 27591829.

12: Liu H, Wang H, Xiang D, Guo W. Pharmaceutical Measures to Prevent Doxorubicin-Induced Cardiotoxicity. Mini Rev Med Chem. 2017;17(1):44-50. Review. PubMed PMID: 27337969.

13: Cruz M, Duarte-Rodrigues J, Campelo M. Cardiotoxicity in anthracycline therapy: Prevention strategies. Rev Port Cardiol. 2016 Jun;35(6):359-71. doi: 10.1016/j.repc.2015.12.004. Epub 2016 May 31. Review. English, Portuguese. PubMed PMID: 27255173.

14: Akam-Venkata J, Franco VI, Lipshultz SE. Late Cardiotoxicity: Issues for Childhood Cancer Survivors. Curr Treat Options Cardiovasc Med. 2016 Jul;18(7):47. doi: 10.1007/s11936-016-0466-6. Review. PubMed PMID: 27230282.

15: Kreidieh FY, Moukadem HA, El Saghir NS. Overview, prevention and management of chemotherapy extravasation. World J Clin Oncol. 2016 Feb 10;7(1):87-97. doi: 10.5306/wjco.v7.i1.87. Review. PubMed PMID: 26862492; PubMed Central PMCID: PMC4734939.

16: Shaikh F, Dupuis LL, Alexander S, Gupta A, Mertens L, Nathan PC. Cardioprotection and Second Malignant Neoplasms Associated With Dexrazoxane in Children Receiving Anthracycline Chemotherapy: A Systematic Review and Meta-Analysis. J Natl Cancer Inst. 2015 Nov 23;108(4). pii: djv357. doi: 10.1093/jnci/djv357. Print 2016 Apr. Review. PubMed PMID: 26598513.

17: Franco VI, Lipshultz SE. Cardiac complications in childhood cancer survivors treated with anthracyclines. Cardiol Young. 2015 Aug;25 Suppl 2:107-16. doi: 10.1017/S1047951115000906. Review. PubMed PMID: 26377717.

18: Edwardson DW, Narendrula R, Chewchuk S, Mispel-Beyer K, Mapletoft JP, Parissenti AM. Role of Drug Metabolism in the Cytotoxicity and Clinical Efficacy of Anthracyclines. Curr Drug Metab. 2015;16(6):412-26. Review. PubMed PMID: 26321196; PubMed Central PMCID: PMC5398089.

19: Conway A, McCarthy AL, Lawrence P, Clark RA. The prevention, detection and management of cancer treatment-induced cardiotoxicity: a meta-review. BMC Cancer. 2015 May 7;15:366. doi: 10.1186/s12885-015-1407-6. Review. PubMed PMID: 25948399; PubMed Central PMCID: PMC4427936.

20: Singh D, Thakur A, Tang WH. Utilizing cardiac biomarkers to detect and prevent chemotherapy-induced cardiomyopathy. Curr Heart Fail Rep. 2015 Jun;12(3):255-62. doi: 10.1007/s11897-015-0258-4. Review. PubMed PMID: 25869733; PubMed Central PMCID: PMC4425995.

Your view history

Dexrazoxane HCl featured